AEON Biopharma gets NYSE American notice for failing additional equity listing standard

AEON Biopharma, Inc. Class A

AEON Biopharma, Inc. Class A

AEON

0.00
  • AEON Biopharma received NYSE American notice dated March 31, 2026 for failing an additional continued listing standard tied to stockholders’ equity.
  • Noncompliance determination cited stockholders’ deficit of about $55 million as of Dec. 31, 2025.
  • Common stock continues to trade on NYSE American under symbol AEON during compliance plan period that runs to Aug. 3, 2026.
  • Ticker retains “.BC” indicator while AEON remains on exchange’s noncompliant issuers list.
  • Exchange may start delisting process if AEON does not regain compliance by Aug. 3, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AEON Biopharma Inc. published the original content used to generate this news brief on April 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.